Chong Kun Dang Pharmaceutical (185750) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Chong Kun Dang Pharmaceutical (185750) has a cash flow conversion efficiency ratio of 0.012x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩12.32 Billion ≈ $8.35 Million USD) by net assets (₩1.03 Trillion ≈ $697.19 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 185750 market cap overview for the company's overall valuation and market capitalisation.
Chong Kun Dang Pharmaceutical - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Chong Kun Dang Pharmaceutical's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Chong Kun Dang Pharmaceutical Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Chong Kun Dang Pharmaceutical ranked by their cash flow conversion efficiency. Explore earnings quality score of Chong Kun Dang Pharmaceutical to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Beijing Advanced Digital Technology Co Ltd
SHE:300541
|
0.141x |
|
Hangzhou Anysoft Information Technology Co Ltd
SHE:300571
|
0.066x |
|
Zambal Spain Socimi SA
MC:YZBL
|
0.008x |
|
Dongwon F & B
KO:049770
|
0.026x |
|
Spearhead Integrated Marketing
SHE:300071
|
-0.011x |
|
China Wuyi Co Ltd
SHE:000797
|
0.016x |
|
Jinhe Biotechnology Co Ltd
SHE:002688
|
0.088x |
|
Guangdong Green Precision Components Co. Ltd.
SHE:300968
|
-0.033x |
Annual Cash Flow Conversion Efficiency for Chong Kun Dang Pharmaceutical (2016–2025)
The table below shows the annual cash flow conversion efficiency of Chong Kun Dang Pharmaceutical from 2016 to 2025. View current stock price of Chong Kun Dang Pharmaceutical for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩1.01 Trillion ≈ $681.99 Million |
₩67.36 Billion ≈ $45.65 Million |
0.067x | -6.68% |
| 2024-12-31 | ₩896.38 Billion ≈ $607.46 Million |
₩64.29 Billion ≈ $43.57 Million |
0.072x | -81.61% |
| 2023-12-31 | ₩815.64 Billion ≈ $552.74 Million |
₩318.16 Billion ≈ $215.61 Million |
0.390x | +257.79% |
| 2022-12-31 | ₩621.29 Billion ≈ $421.04 Million |
₩67.73 Billion ≈ $45.90 Million |
0.109x | +378.04% |
| 2021-12-31 | ₩565.81 Billion ≈ $383.44 Million |
₩12.90 Billion ≈ $8.74 Million |
0.023x | -87.94% |
| 2020-12-31 | ₩551.59 Billion ≈ $373.81 Million |
₩104.32 Billion ≈ $70.70 Million |
0.189x | +16.22% |
| 2019-12-31 | ₩474.95 Billion ≈ $321.87 Million |
₩77.29 Billion ≈ $52.38 Million |
0.163x | +64.50% |
| 2018-12-31 | ₩430.90 Billion ≈ $292.01 Million |
₩42.63 Billion ≈ $28.89 Million |
0.099x | -51.15% |
| 2017-12-31 | ₩403.29 Billion ≈ $273.31 Million |
₩81.67 Billion ≈ $55.35 Million |
0.203x | +24.15% |
| 2016-12-31 | ₩354.25 Billion ≈ $240.07 Million |
₩57.79 Billion ≈ $39.16 Million |
0.163x | -- |
About Chong Kun Dang Pharmaceutical
Chong Kun Dang Pharmaceutical Corp. manufactures, markets, and sells medicines in South Korea and internationally. It offers prescription drugs for anti-hypertension, anti-hyperlipidaemia, and anti-diabetics, as well as immunosuppressants; over-the-counter medicines; and consumer health products, such as insecticides and hair dye products, as well as health supplements. The company was founded in… Read more